logo

For the Inventor, By the Inventor

Berlin, Germany

Silence Therapeutics Gmbh

Calculating rank
USPTO Granted Patents = 38

% Expired Patents = 39.5



Trademarks = 3

Forward Citations = 196

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Jörg Kaufmann (20 out of 33 patents)

silverMedal Christian Frauendorf (12 out of 12 patents)

bronzeMedal Klaus Giese (12 out of 28 patents)

4.  Anke Klippel-Giese (12 out of 17 patents)

5.  Judith Hauptmann (10 out of 10 patents)

6.  Adrien Weingärtner (10 out of 10 patents)

7.  Lucas Bethge (10 out of 13 patents)

8.  Ansgar Santel (6 out of 9 patents)

9.  Dmitry Samarsky (5 out of 5 patents)

10.  Sibylle Dames (5 out of 5 patents)

11.  Oliver Keil (5 out of 14 patents)

12.  Stephan Tenbaum (3 out of 3 patents)

13.  Steffen Schubert (3 out of 3 patents)

14.  Ute Schaeper (3 out of 3 patents)

15.  Alison Gallafent (2 out of 2 patents)


Core Competencies:
Nucleic Acids
Interfering RNA
Gene Expression
Lipid Complexes
TMPRSS6
LPA
VEGFR1
ANG2
Phosphorodithioate
Oligonucleotide-Ligand Conjugates
Protein Kinase N Beta
Trivalent Glycoconjugate

38 patents:

1. 12760306 - siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND (2026-10-13),
2. 12084656 - Products and compositions (2024-09-10),
3. 12076335 - Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators (2024-09-03),
4. 12054717 - Nucleic acids for inhibiting expression of LPA in a cell (2024-08-06),
5. 11987794 - Products and compositions (2024-05-21),
6. 11912993 - Nucleic acid linked to a trivalent glycoconjugate (2024-02-27),
7. 11873489 - Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages (2024-01-16),
8. 11820971 - Nucleic acids for inhibiting expression of PROS1 in a cell (2023-11-21),
9. 11753642 - Nucleic acids for inhibiting expression of C3 in a cell (2023-09-12),
10. 11578328 - Interfering RNA molecules (2023-02-14),
11. 11560563 - SiRNAs with vinylphosphonate at the 5' end of the antisense strand (2023-01-24),
12. 11499153 - Nucleic acids for inhibiting expression of LPA in a cell (2022-11-15),
13. 11414660 - Products and compositions (2022-08-16),
14. 11319537 - Nucleic acids for inhibiting expression of LPA in a cell (2022-05-03),
15. 11299738 - Further novel oligonucleotide-ligand conjugates (2022-04-12),
Company Overview
Silence Therapeutics GmbH, based in Berlin, specializes in the development of RNA-targeted therapeutics. The company focuses on harnessing the potential of RNA interference (RNAi) technology to create innovative treatments for various diseases, including genetic disorders and cancers. With a commitment to advancing precision medicine, Silence Therapeutics aims to address unmet medical needs through its proprietary platform, which enables the design and delivery of RNA-based therapies tailored to specific conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Silence Therapeutics Gmbh USPTO Patent Assignee Logo
38 Patents

#28 in D-1000 Berlin

#1,343 in Germany

#17,870 in the World

Berlin, DE
Berlin, Germany

Silence Therapeutics Gmbh

Forward Citations = 196

25 inventors:

goldMedal Jörg Kaufmann (20 out of 33 patents)

silverMedal Christian Frauendorf (12 out of 12 patents)

bronzeMedal Klaus Giese (12 out of 28 patents)

4.  Anke Klippel-Giese (12 out of 17 patents)

5.  Judith Hauptmann (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Silence Therapeutics Gmbh. Retrieved from https://idiyas.com/company/silence-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…